Inhibitor Therapeutics, Inc. SEC filings INTI
Inhibitor Therapeutics, Inc. has 724 filings in SEC EDGAR's recent list, going back to Jul 21, 1997. Its latest annual report, Form 10-K, was filed on Mar 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (officer or director change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Aug 17, 2026 | Aug 17, 2026 |
| DEF 14C | Information statement | Dec 5, 2019 | Dec 5, 2019 |
| DEF 14C | Information statement | Jun 3, 2019 | Jun 3, 2019 |
| PRE 14C | Filing | May 24, 2019 | May 24, 2019 |
| DEF 14C | Information statement | Jan 8, 2019 | Dec 21, 2018 |
| PRE 14C | Filing | Dec 28, 2018 | Dec 21, 2018 |
| DEF 14C | Information statement | Dec 21, 2018 | Dec 21, 2018 |
| DEF 14A | Proxy statement | Nov 13, 2017 | Dec 18, 2017 |
| DEF 14C | Information statement | Dec 5, 2016 | Dec 5, 2016 |
| DEF 14C | Information statement | Apr 25, 2016 | Apr 25, 2016 |
| PRE 14C | Preliminary information statement | Apr 12, 2016 | Apr 12, 2016 |
| DEF 14C | Information statement | Jun 16, 2015 | Jun 16, 2015 |
| PRE 14C | Preliminary information statement | Jun 3, 2015 | Jun 15, 2015 |
| DEF 14C | Information statement | Oct 14, 2014 | Oct 14, 2014 |
| PRE 14C | Preliminary information statement | Oct 3, 2014 | Oct 3, 2014 |
| PREM14A | Prem 14a | Oct 28, 2010 | Dec 20, 2010 |
| PRE 14A | Preliminary proxy statement | Feb 2, 2010 | Feb 2, 2010 |
| DEF 14A | Proxy statement | Sep 17, 2009 | Oct 9, 2009 |
| PRE 14A | Preliminary proxy statement | May 18, 2009 | Jun 19, 2009 |
| DEF 14A | Proxy statement | Oct 30, 2008 | Dec 5, 2008 |
| DEF 14A | Proxy statement | Apr 12, 2007 | May 18, 2007 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2007 | Apr 2, 2007 |
| DEF 14A | Proxy statement | Jan 8, 2007 | Jan 9, 2007 |
| PRE 14A | Preliminary proxy statement | Dec 28, 2006 | Feb 9, 2007 |
| DEF 14A | Proxy statement | Apr 12, 2006 | May 19, 2006 |
| DEF 14A | Proxy statement | Apr 8, 2005 | May 20, 2005 |
| PRE 14A | Preliminary proxy statement | Mar 28, 2005 | May 20, 2005 |
| DEF 14A | Proxy statement | Apr 19, 2004 | May 14, 2004 |
| PRE 14A | Preliminary proxy statement | Mar 30, 2004 | May 14, 2004 |
| DEF 14A | Proxy statement | Apr 15, 2003 | May 15, 2003 |
| DEF 14A | Proxy statement | Apr 10, 2002 | May 23, 2002 |
| PRE 14A | Preliminary proxy statement | Mar 27, 2002 | May 23, 2002 |
| DEF 14A | Proxy statement | Apr 9, 2001 | Dec 31, 2000 |
| DEF 14A | Proxy statement | Mar 30, 2000 | Apr 27, 2000 |
| DEF 14A | Proxy statement | Mar 15, 1999 | Apr 15, 1999 |
| DEF 14A | Proxy statement | Mar 20, 1998 | Apr 14, 1998 |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INTI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1042418
- Former names
- HedgePath Pharmaceuticals, Inc. (until Aug 12, 2019); COMMONWEALTH BIOTECHNOLOGIES INC (until May 20, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.